LLCP Names Michael Weinberg and Matthew Frankel as Co-Chairs of Investment Committee
Michael Weinberg joined LLCP in 2008. Michael is responsible for LLCP's global investment activities which include deal origination and structuring, sector strategy, and capital markets activities. In addition, Michael oversees the Firm's Investor Relations Team and capital raising activities. Michael is Co-Chairperson of the Investment Committee and a member of the Executive Committee.
Matthew Frankel joined LLCP in 2010. Matthew is responsible for LLCP's global investment activities which include sector strategy, deal structuring and due diligence, portfolio management and oversight of the U.S. Investment Team. Matthew is Co-Chairperson of the Investment Committee and a member of the Executive Committee.
Arthur Levine and Lauren Leichtman, the firm's Co-Founders, will continue to support LLCP through their role as Co-Chairpersons of the Executive Committee and members of the Firm's Investment Committee.
Mr. Levine and Ms. Leichtman said, 'We are excited to continue our succession plan to ensure the future success of LLCP. LLCP is more than just a commitment - it's the legacy we've built and the passion we'll carry forward. Mike and Matt have proven their dedication and commitment to LLCP, not only by leading the Firm's robust growth, but by also developing its future leaders. We are deeply grateful for the steadfast support of our investment partners, whose expertise and vision continue to shape our success. With their invaluable contributions and our leadership team's dedication, we are poised to create lasting value and drive forward meaningful opportunities.
Messrs. Weinberg and Frankel said, 'We are privileged to build upon LLCP's legacy of excellence, fueled by the dedication of our world-class team. Our investment philosophy, which has successfully navigated numerous market cycles, will remain unchanged. We deeply appreciate the opportunity to continue our work leading the firm's bright future and are ever more confident about our future success.
About Levine Leichtman Capital Partners
Levine Leichtman Capital Partners, LLC is a middle-market private equity firm with a 41-year track record of investing across various targeted sectors, including Business Services, Franchising & Multi-unit, Education & Training and Engineered Products & Manufacturing. LLCP utilizes a differentiated Structured Private Equity investment strategy, combining debt and equity capital investments in portfolio companies. LLCP believes that by investing in a combination of debt and equity securities, it offers management teams growth capital in a highly tailored, flexible investment structure that can be a more attractive alternative than traditional private equity.
LLCP's global team of dedicated investment professionals is led by 9 partners who have worked at LLCP for an average of 19 years. Since inception, LLCP has managed approximately $16.4 billion of institutional capital across 15 investment funds and has invested in over 100 portfolio companies. LLCP and its affiliates currently manage approximately $11 billion of assets and has offices in Los Angeles, New York, Chicago, Miami, London, Stockholm, Amsterdam and Frankfurt.
Media Contact: Isabel Moon, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/llcp-names-michael-weinberg-and-matthew-frankel-as-co-chairs-of-investment-committee-302463843.html
SOURCE Levine Leichtman Capital Partners, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Vireo Growth Inc (VREOF) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions
Pro Forma Revenue: $90.7 million. Adjusted EBITDA: $23.2 million, with a margin of approximately 25%. Second Quarter GAAP Revenue: $48.1 million, a 91.4% increase year over year. Gross Margin: 51.6%, a reduction of 260 basis points compared to the prior year quarter. SG&A Expenses: $12.2 million, 25.4% of sales, an improvement of 480 basis points compared to Q2 last year. Adjusted Operating Income: $11.3 million, 23.5% of sales. Cash on Hand: $106.2 million at the end of Q2. Total Current Assets: $186.2 million, excluding New York assets held for sale and income taxes receivable. Total Current Liabilities: $51.8 million, excluding New York liabilities held for sale and refinanced debt. Corporate SG&A Costs: $1.8 million, a reduction of approximately 40% from the prior year quarter. Shares Outstanding: 158,617,377 shares on the Treasury method basis. Warning! GuruFocus has detected 9 Warning Signs with VREOF. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Vireo Growth Inc (VREOF) reported a significant increase in GAAP revenue, up 91.4% year over year, driven by contributions from recent merger transactions. The company successfully closed three merger transactions, expanding its operational portfolio to six states and improving profitability and cash generation. Vireo Growth Inc (VREOF) completed a $153 million refinancing event, reducing annual interest expenses by approximately $10 million and increasing cash on hand to over $100 million. The company achieved an adjusted EBITDA margin of approximately 25%, with adjusted EBITDA of $23.2 million. SG&A expenses, excluding severance, improved by 480 basis points compared to the previous year, indicating better cost management. Negative Points GAAP gross margin was negatively impacted by termination fees related to a prior agreement, resulting in a reduction of 260 basis points compared to the prior year quarter. The company's performance in Minnesota was softer, affecting overall gross margin. Vireo Growth Inc (VREOF) faces uncertainty regarding the timing of adult-use cannabis sales in Minnesota, which could impact future revenue. The company is still awaiting regulatory approval for the divestment of New York assets, which could delay strategic plans. Price deflation and competition from hemp in markets like Nevada and Missouri pose challenges to maintaining market share and profitability. Q & A Highlights Q: Can you discuss the impact of the licensing agreement with Curio on your New York assets and distribution network? A: John Mazarakis, CEO & Co-Executive Chairman: The partnership with Curio does not affect the divestiture of our New York assets. Curio is a leading brand in the nutraceutical space, and we see no cannibalization with our current SKUs. We are optimistic about this relationship. Q: With the recent refinancing, what are your capital management priorities, and are there any M&A opportunities on the horizon? A: John Mazarakis, CEO & Co-Executive Chairman: We are engaging in M&A discussions, focusing on both distressed and mature spaces. While we are hopeful for M&A in the next 12 to 24 months, our primary focus remains on organic growth and achieving positive free cash flow at the unit level. Q: Can you provide an update on the Arches platform and its potential impact on growth? A: John Mazarakis, CEO & Co-Executive Chairman: We are working on deploying the Arches delivery platform. Delivery is available in all states where it is permitted, and we continue to invest in this service as we believe in its potential. Q: What preparations are being made for recreational cannabis sales in Minnesota, and how do you foresee the rollout? A: John Mazarakis, CEO & Co-Executive Chairman: We anticipate a shortage of supply in Minnesota, with initial supply coming from us and GTI. We are working with the state to ensure readiness and expect to begin adult-use sales in the second half of this year. Our retail footprint remains limited to eight locations. Q: Can you clarify the situation with your New York assets and potential partnerships there? A: John Mazarakis, CEO & Co-Executive Chairman: We are committed to a buyer for our New York assets, pending regulatory approval. Our partners have a wide network, and we aim to become the largest supplier of indoor flower in New York, leveraging this partnership. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
28 minutes ago
- Yahoo
Kamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...
Total Revenue (First Half 2025): $88.8 million, up 11% year over year. Total Revenue (Q2 2025): $44.8 million, up 5% year over year. Adjusted EBITDA (First Half 2025): $22.5 million, up 35% year over year, representing a 25% margin. Adjusted EBITDA (Q2 2025): $10.9 million, up 20% year over year. Gross Profit (Q2 2025): $18.9 million with a 42% margin. Gross Profit (First Half 2025): $39.7 million with a 45% margin. Net Income (Q2 2025): $7.4 million or $0.13 per diluted share. Net Income (First Half 2025): $11.3 million or $0.19 per diluted share. Operating Expenses (Q2 2025): $11.9 million. Cash Provided by Operating Activities (Q2 2025): $8 million. Cash Balance (End of First Half 2025): $66 million. Annual Revenue Guidance 2025: $178 million to $182 million. Adjusted EBITDA Guidance 2025: Increased to $40 million to $44 million. Warning! GuruFocus has detected 4 Warning Sign with KMDA. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kamada Ltd (NASDAQ:KMDA) reported strong financial results for the first half of 2025, with total revenues of $88.8 million, representing an 11% year-over-year increase. Adjusted EBITDA for the first half of 2025 was $22.5 million, up 35% year-over-year, indicating improved profitability. The company increased its adjusted EBITDA guidance for 2025 to between $40 million and $44 million, reflecting confidence in continued profitable growth. Kamada Ltd (NASDAQ:KMDA) is advancing its PIVOTAL phase 3 inhaled clinical program, which could lead to significant future growth opportunities. The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars later this year, contributing to future revenue growth. Negative Points Gross profit margins decreased in the second quarter of 2025 compared to the same period in 2024, due to changes in product and territory sales mix. Operating expenses, although managed well, still represent a significant portion of revenues, which could impact future profitability if not controlled. The company's net income, while improved, is still subject to fluctuations due to changes in financial and tax expenses. The competitive landscape for Kamada Ltd (NASDAQ:KMDA)'s inhaled AAT program is evolving, with other companies developing alternative technologies that could impact market share. The company's cash position, although strong, has declined over the last couple of quarters, which may limit the scale of future business development and M&A activities. Q & A Highlights Q: Can you provide insights into the dynamics behind KEDRAB and CYTOGAM, which have been growth drivers in the past? Are they performing as expected? A: Amir London, CEO: KEDRAB and CYTOGAM are performing according to expectations. KEDRAB is supplied based on inventory management, and CYTOGAM is progressing as planned. Growth is anticipated once additional clinical data is available. The diversity of our portfolio, including products like GLASSIA and VARIZIG, supports our continued growth. Q: With a solid cash position, is it sufficient for impactful business development? How do you balance internal investments and external business development? A: Amir London, CEO: We plan to use existing cash and have additional funding sources if needed. We are focused on commercial stage assets, particularly in plasma-derived products and specialty pharma. We are actively screening multiple targets and expect meaningful impact on our 2026 performance. Q: Can you describe the competitive landscape for the inhaled AAT program? Are there developments that might change the market opportunity? A: Amir London, CEO: Our inhaled program is the most advanced in terms of efficacy studies. The market is growing, and we expect it to be a $2 billion market by the time we have study results. Our technology offers better ease of use and quality of life, positioning us as a strong competitor. Q: Was there any one-time sales impact in the distribution revenue segment this quarter? How should we view this channel going forward? A: Amir London, CEO: There were no one-time sales. The launch of the biosimilar product builds on our existing infrastructure, and we expect continued growth. This will help improve our margins over the next few years. Q: What was responsible for the tax credit in the June quarter, and what do you expect the tax rate to be in the future? A: Chaime Orlev, CFO: Fluctuations in currency exchange affected our tax results. We anticipate utilizing all tax loss carryforwards by the end of 2025, moving into tax payments. The effective tax rate is expected to be between 20% and 25% in 2026 and beyond. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
28 minutes ago
- Yahoo
RGC Resources Inc (RGCO) Q3 2025 Earnings Call Highlights: Strong Growth in Net Income and Gas ...
Net Income (Q3 2025): $538,000 or $0.05 per share, compared to $157,000 or $0.02 per share in Q3 2024. Year-to-Date Net Income (2025): $13.5 million or $1.31 per share, a 16% increase from $1.15 per share in the same period of 2024. Delivered Gas Volumes (Q3 2025): Increased by 6% compared to Q3 2024. Year-to-Date Delivered Gas Volumes (2025): Increased by 15% compared to 2024. Capital Expenditures (Year-to-Date 2025): $15.7 million, down approximately 5% from the same period in 2024. New Main Miles Installed (2025): 3.9 miles, 50% higher than the total installed in fiscal 2024. New Services Connected (2025): 541 new services through June 30. Roanoke Gas Margins: Higher base rates contributed to increased margins. Interest Expense: Lower in the current quarter compared to the prior year. Balance Sheet: Strong, with renewed Roanoke Gas line of credit and increased maximum availability to $30 million. Debt Refinancing: New note for Midstream debt at SOFR plus 1.55%, with plans to swap to a fixed rate. Full-Year Earnings Per Share Forecast (2025): $1.22 to $1.27, with an anticipated modest net loss in Q4. Warning! GuruFocus has detected 9 Warning Signs with RGCO. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points RGC Resources Inc (NASDAQ:RGCO) experienced strong main extensions and steady renewal activity, with 3.9 new main miles installed, a 50% increase over the previous year. The company reported a 6% increase in total delivered gas volumes for the quarter, driven by high consumption from an industrial customer. Net income for the first nine months of fiscal 2025 increased by 16% compared to the same period in 2024, reaching $13.5 million or $1.31 per share. RGC Resources Inc (NASDAQ:RGCO) successfully refinanced its Midstream debt, securing a new seven-year note with favorable interest rates, providing financial stability. The company is benefiting from regional economic development, including a significant investment by Google, which is expected to drive future growth opportunities. Negative Points Residential and commercial gas volumes were slightly down compared to the same quarter in the prior year. The company anticipates a modest net loss in the fourth quarter due to weather-sensitive revenue and earnings being concentrated in the first and second quarters. Capital expenditure for the year is expected to be lower than the previous year, with some planned investments pushed to fiscal 2026. Inflation and higher interest rates continue to impact the company's expenses, with contract renewals exceeding national inflation rates. The Franklin County expansion has been delayed, with capital investment allocation moved to fiscal 2026. Q & A Highlights Q: Looking at the 2025 capital forecast, with minimal MVP growth this year and the refinancing, do you expect MVP growth to increase in 2026? Also, will Google-related investments lead to increased customer growth and system expansion? A: Yes, we expect MVP growth to be significantly higher in 2026, particularly with the Franklin County expansion. Our SAVE Rider spending will likely remain consistent, and customer growth could increase, especially with developments like Google's. We're optimistic about maintaining or improving customer growth and system expansion next year. (Paul Nester, President & CEO) Q: Is there significant growth opportunity along existing mains due to higher electricity rates in the region? A: Yes, we actively conduct saturation studies to identify potential customers along existing mains. The increase in electricity rates, driven by factors like the Virginia Clean Economy Act, has led to steady conversions to natural gas. We expect this trend to continue, as electricity rates are unlikely to decrease soon. (Paul Nester, President & CEO) Q: Can you provide more details on the refinancing agreement for Midstream's debt? A: We reached an agreement with two banks for a new note to refinance all Midstream-related debt. This seven-year note will carry interest at SOFR plus 1.55%, and we plan to swap the variable rate to a fixed rate. This refinancing positions us well for future investments and manageable amortization. (Timothy Mulvaney, CFO) Q: How is the economic development in the region impacting RGC Resources? A: The recent Google announcement is a significant development for the region, likely the largest investment ever made here. We continue to work with localities and the Roanoke Regional Partnership on various opportunities. The operational MVP pipeline is generating interest across industries, enhancing our position in the region. (Paul Nester, President & CEO) Q: What are the expectations for the fourth quarter and full-year earnings? A: We anticipate a modest net loss in the fourth quarter due to weather-sensitive volumes. However, we maintain our full-year earnings per share range of $1.22 to $1.27. We continue to monitor inflation and interest rates while managing expenses prudently. (Paul Nester, President & CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤
